Select therapeutic use:
Indications for Eprosartan:
Monotherapy: not volume depleted: initially 600mg once daily. Usual range: 400–800mg/day given as a single dose or in two divided doses. Moderate-to-severe renal impairment: max 600mg daily.
Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before beginning therapy or monitor closely. Monitor BP, renal function, electrolytes. Renal artery stenosis. Severe CHF. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; avoid. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). May be antagonized by, and renal toxicity potentiated by NSAIDs, including COX-2 inhibitors; monitor renal function periodically in elderly and/or volume-depleted. May increase lithium levels; monitor.
Angiotensin II receptor blocker (ARB).
Viral infection, injury, fatigue, abdominal pain, hypertriglyceridemia, arthralgia, depression, urinary tract or upper respiratory tract infection, rhinitis, pharyngitis, coughing, hypotension, rhabdomyolysis (rare).
Formerly known under the brand name Teveten.
Hepatic. 98% protein bound.